

# CardieX Ltd

16:03 20 Aug 2020

## CardieX subsidiary ATCOR enters improved agreement with global pharma giant Bayer

CardieX Ltd (ASX:CDX) subsidiary ATCOR and global pharmaceutical company Bayer AG (OTCMKTS:BAYZF) have entered a new amended agreement for the lease of ATCOR devices and the provision of expanded data management services for Bayer's 'AVANTI' trial.

Bayer, which has a market cap of approximately US\$17 billion, originally contracted ATCOR to provide clinical trial lab and data management services as well as devices for the AVANTI trial through to October 2020, with a contract value of US\$1.26 million.

The total value of this contract and ongoing trial has been increased by US\$420,000 to US\$1.68 million under the new amended agreement.

Shares hit 6.8 cents today, a new high of almost four years, before closing at 5.4 cents on volume of more than 23 million.

### "Ongoing business development success"

CDX managing director and CEO Craig Copper said: "This new contract amendment is testament to the ongoing business development success of the company as we continue to move through this difficult economic period.,

"It is further validation of the unique capabilities of our FDA-cleared SphygmoCor® technology that the company is actively expanding into wearables, smart devices and other new markets".

In addition, the term of the contract has been extended through to June 2021 with the additional AVANTI amended contract revenue to be accrued by the company in the current FY 2021.

The AVANTI trial is one of two ongoing trials that ATCOR has under contract with Bayer - the other being the CONCORD trial.

### Impact of new amended contract

Impacts of the new amended contract and new revenues include:

- ATCOR XCEL system lease extension through June 2021;
- 185 incremental patient visits for a total of 2,538 patient visits;
- Increase in contract value - of US\$420,000; and
- Total contract value - US\$1.68 million.

ATCOR's XCEL device is the only FDA cleared device for measuring the central aortic waveform and reporting on associated clinical data in all adult subjects.

XCEL is used by clinicians, research institutions, and pharmaceutical companies in monitoring critical hemodynamic data during patient treatment and drug trials in multiple clinical settings and for multiple disease states.

**Price:** 0.083

**Market Cap:** \$76.72 m

### 1 Year Share Price Graph



March 2020 September 2020 February 2021

### Share Information

**Code:** CDX

**Listing:** ASX

**52 week High Low**  
0.115 0.014

**Sector:** Medical technology & services

**Website:** www.cardieX.com

### Company Synopsis:

CardieX &nbsp;Ltd (ASX:CDX) is a Sydney-based health technology company that previously traded as AtCor Medical Holdings (ACG) on the Australian Securities Exchange.

action@proactiveinvestors.com.au

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 [action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of CardieX Ltd named herein, including the promotion by the Company of CardieX Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).